What changed recently
Newly published and updated guidelines across every system, newest first. Each entry links to the official source.
7 older updates are outside this window. Show all time
- Hematology & OncologyUS2026-04-162022 → 2022, amended 2026Prostate cancer
AUA amended the 2022 guideline after a literature review covering July 2021 to December 2024 (29 studies plus a set on artificial intelligence in disease management). The society describes the amendment as refining risk-based management, updating imaging and radiation therapy guidance, and strengthening the shared decision-making statements.
- Hematology & OncologyEU2026-04-142023 → 2026Colorectal cancer
ESMO replaced its 2023 metastatic colorectal cancer guideline with the 2026 edition (Cremolini et al., Ann Oncol 37(6):759-776); the 2023 document is now marked superseded in this atlas.
- Hematology & OncologyEU2026-01-012025 → 2026 editionProstate cancer
The EAU panel describes the 2026 text as a limited update of the 2025 publication, with revised evidence summaries and recommendations for MRI in biopsy indication and strategy, for staging, and for active surveillance strategy, plus an adapted EAU risk-group table for localised and locally advanced disease.
- Hematology & OncologyUS2026-01-012026.1.0 → 2026.1.1Multiple myeloma
This living-guideline version bump revisits the evidence base from a February 2026 literature search and issues updated recommendations covering the teclistamab plus daratumumab combination; the preceding 2026.1.0 release had itself replaced the 2019 guideline by adding first-ever guidance on smoldering myeloma and incorporating CAR T-cell, bispecific antibody and antibody-drug conjugate options.
source ↗curation confidence 90% - Hematology & OncologyUS2025-12-012020 → 2025 updateLeukemia
The 2025 ASH panel retired the 2020 guideline's split between "intensive" and "non-intensive" therapy, framing recommendations instead around candidacy for antileukaemic therapy, and it now positions venetoclax-based combinations alongside conventional induction and post-remission therapy for older adults with newly diagnosed AML.
source ↗curation confidence 90% - Hematology & OncologyUS2025-10-012.2025 → 3.2025Lymphoma
NCCN's published Insights article for this version bump describes the panel's discussion of newly incorporated data in three areas: CD3xCD20 bispecific antibodies and CD19-directed antibodies/antibody-drug conjugates in relapsed or refractory follicular lymphoma, BTK inhibitor-based regimens in TP53-mutated classical mantle cell lymphoma, and bispecific antibodies added to chemoimmunotherapy in relapsed or refractory DLBCL.
source ↗curation confidence 90% - Hematology & OncologyEU2025-07-072021 → 2025Multiple myeloma
The EHA-EMN 2025 guideline replaced the 2021 EHA-ESMO guideline, adopting the R2-ISS staging system and adding minimal residual disease, circulating plasma cells and mass-spectrometry monoclonal protein as prognostic factors, alongside 14 novel EMA/FDA-approved regimens.